This website uses cookies to help us give you the best experience when you visit our website. By continuing to use this website, you consent to our use of these cookies.

Find out more about how we use cookies and how to manage them by reading our cookie notice.

Posted 30 Sep 2013

Phase I results for AZD9291 at the European Cancer Congress 2013

About the author

Darren Cross

Darren Cross

View author

Other articles from this author

Follow AstraZeneca: